By the Top Tier Newswire AI Desk · November 2, 2026 at 9:50 AM ET · reviewed against 5 wire stories
UNIQURE N V (QURE) is down -6.81% in the latest session. Our newswire has captured 5 stories on QURE across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
uniQure shares fell 6.81% to $23.14 on Monday. The primary driver was a sharp intraday reversal following the FDA’s acceptance of the company’s biologics license application for ifezuntirgene inilparvovec, a gene therapy for Huntington’s disease.
What Happened
uniQure announced on November 2, 2026, that the FDA had accepted its BLA for ifezuntirgene inilparvovec and granted it priority review. The company filed a Form 8-K with the SEC to disclose the news. While the regulatory milestone is significant, the stock experienced volatile trading. Analysts have recently adjusted their views on the company. Barclays downgraded uniQure to Equal-Weight and lowered its price target to $28. RBC Capital maintained an Outperform rating but cut its price target to $48. Goldman Sachs kept a Neutral stance and reduced its price target to $31. The company is scheduled to report its third-quarter 2026 financial results on November 4, 2026.
What The Data Shows
The session began with a +5.9% gap, opening at $26.30 against a prior close of $24.83. The stock reached a session high of $33.94 at 7:05 AM ET before sliding to a session low of $22.42 at 9:45 AM ET. Volume stood at 1.8 million shares, which is 0.9 times the three-month daily average. The stock has a market capitalization of $1.7 billion and remains unprofitable with a trailing twelve-month EPS of -4.04. Revenue grew 30.2% over the same period. The 52-week range is $8.73 to $69.99. Over the last eight sessions, the stock had moved up 9.4% from $22.69 to $24.83. On November 2, the stock printed two fresh 52-week highs and ten fresh 52-week lows. Retail traders on r/wallstreetbets are discussing the stock, with one user noting a significant loss over the past year.
What To Watch
Investors will focus on the third-quarter 2026 financial results scheduled for release on November 4, 2026. The market will also monitor how the FDA’s priority review status influences future analyst price targets and the company’s valuation metrics.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
QURE · today's session (5-min) · -5.72% vs prior close · updated 3:29 PM ETAI sentiment, last 36h · averaged over 5 stories · 60/100 bullish
The headlines behind the move
Story flow · 5 stories on the wire, last 36h · hover or tap a dot for the headline
7h agoTipRanksBULLISH 64Product/PR
uniQure FDA Accepts Huntington’s Therapy BLA for Priority Review
An update from uniQure ( ($QURE) ) is now available. On November 2, 2026, uniQure said the FDA had accepted its BLA for ifezuntirgene inilparvovec, an investigation...
7h agoGuruFocusBULLISH 58Product/PR
FDA Accepts uniQure's BLA for Huntington's Gene Therapy, Ticker QURE Sees Mixed Signals
7h agoThe FlyBULLISH 64Product/PR
uniQure announces FDA acceptance, priority review for ifezuntirgene inilparvovec
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →